Clinical Trial Update: A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetic study evaluating JDQ443 in participants with hepatic impairment compared with matched healthy controls has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• JDQ443 (JDQ443)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Small Cell Lung Carcinoma | Phase 1 | Status: COMPLETED